当前位置:首页 >财报库 > 报告详情

吉利德科学Gilead Sciences(GILD)2025年第一季度财报「NASDAQ」(英文版)(129页).pdf

上传人: Kell****reet 编号:653913 2025-05-20 129页 1.05MB

下载:

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549 FORM 10-QQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March 31,2025orTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For

2、the transition period from _ to _Commission File No.0-19731 GILEAD SCIENCES,INC.(Exact Name of Registrant as Specified in Its Charter)Delaware94-3047598(State or Other Jurisdiction of Incorporation or Organization)(IRS Employer Identification No.)333 Lakeside Drive,Foster City,California 94404(Addre

3、ss of principal executive offices)(Zip Code)650-574-3000(Registrants Telephone Number,Including Area Code)Securities registered pursuant to Section 12(b)of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Stock,par value,$0.001 per shareGILDThe Nasdaq Globa

4、l Select MarketIndicate by check mark whether the registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subje

5、ct to such filingrequirements for the past 90 days.Yes x No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T(232.405 of this chapter)during the preceding 12 months(or for such shorter

6、 period that the registrant was required to submit suchfiles).Yes x No Indicate by check mark whether the registrant is a large accelerated filer,an accelerated filer,a non-accelerated filer,a smaller reporting company or anemerging growth company.See the definitions of“large accelerated filer,”“acc

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文是Gilead Sciences, Inc.(吉利德科学公司)2025年第一季度10-Q报告的摘录,主要内容包括: 1. 公司简介:Gilead是一家生物科技公司,专注于治疗HIV、肝病和癌症等疾病。 2. 财务数据:2025年第一季度,公司总收入为66.67亿美元,净利润为13.15亿美元,每股摊薄后盈利1.04美元。 3. 重要事项:公司完成了对CymaBay Therapeutics的收购,并与Galapagos和LEO Pharma建立了战略合作关系。 4. 法律诉讼:公司面临多起与药品专利、反垄断和产品责任相关的诉讼,部分案件已达成和解或判决。 5. 未来展望:公司将继续推进产品研发和市场拓展,以实现长期增长。
吉利德科学公司2025年第一季度财务状况如何? 吉利德科学公司面临哪些主要法律诉讼和调查? 吉利德科学公司2025年第一季度收入和利润情况如何?
客服
商务合作
小程序
服务号
折叠